POTENT ANTISENSE OLIGONUCLEOTIDES TO APO(A) NORMALIZE PLASMA LP(A) LEVELS IN THE MAJORITY OF PEOPLE WITH ELEVATED LP(A): RESULTS OF ISIS-APO(A)RX PHASE 2 AND ISIS-APO(A)-LRX PHASE 1 TRIALS

Nick Viney,Santica Marcovina,Shuting Xia,Richard Geary,Joseph L. Witztum,Sotirios Tsimikas

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2016）

Cited 2|Views9

No score

Abstract

Elevated Lp(a) levels are causal, independent predictors of CVD and aortic stenosis (AS). Specific therapies to potently lower Lp(a) are lacking. We assessed the safety and efficacy of ISIS-APO(a)Rx in patients with elevated Lp(a) and of ISIS-APO(a)-LRx, an optimized antisense oligonucleotide (ASO)

Translated text

Key words

oligonucleotides,isis-apo,isis-apo

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined